PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Diverse task force develops new quality measures to improve lupus care by 2030

2023-11-07
(Press-News.org) ATLANTA — Leaders of a project to develop and implement equitable new quality measures for lupus care by the end of the decade will present their work at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting (Abstract #1899).

Systemic lupus erythematosus (SLE, lupus) is an autoimmune disease marked by adaptive immune system activation, formation of autoantibodies, and systemic inflammation affecting organ systems throughout the body. Lupus disproportionately affects women and people of color, who are more likely to have severe disease and experience disparities in care.

To help improve health care quality, safety, and outcomes for all patients with lupus and address long-standing inequities, the ACR partnered with the Centers for Disease Control and Prevention (CDC) to develop five new quality measures for lupus clinical care. The project, called Healthy People with Lupus 2030, was co-chaired by Jinoos Yazdany, M.D., MPH, Chief of Rheumatology at San Francisco General Hospital and Christie Bartels, M.D., MS, Chief of Rheumatology at the University of Wisconsin.

Two interdisciplinary teams worked on the project. One focused on electronic health records (EHR)-based quality measures related to hydroxychloroquine, steroid use, and renal screenings. The other looked at patient-reported outcome measures (PROMs). Both teams used literature reviews, modified Delphi techniques (a communication technique that relies on a panel of experts), and extensive patient input to develop the quality measures.

The clinical measures workgroup extracted quality measures from guidelines, rated them by importance and feasibility, then voted on them in three Delphi sessions based on importance to patients, feasibility of measurement, and public health impact. Measures with consensus on feasibility and importance were ranked to identify the top three.

For PROMs, the experts reviewed quality-of-life domains (depression, pain cognition, etc.) in lupus in tandem with a patient advisory panel composed of people from communities most affected by the disease. Patients helped select the final measures and were, as Yazdany says, “key to the success of the project.”

Ultimately, the teams and their patient partners settled on five key priorities for Healthy People with Lupus 2030:

Increase hydroxychloroquine use Reduce glucocorticoids to no more than 7.5 mg a day for a maximum six months Monitor bi-annually for lupus nephritis Reduce disability among people with lupus Reduce depression and suicide among lupus patients Yazdany notes that the dose and duration of steroids are just below the threshold where the drugs are known to cause “significant harm,” but that most people, even those with lupus nephritis, should be below 7.5 mg by six months.

“We hope that the steroid threshold will be further lowered in future measure revisions as scientific evidence supporting the safe use of lower doses, even for the most severe lupus manifestations, becomes stronger,” she says.

Another problem for lupus patients is the lack of mental health providers, especially in rural areas, who can address depression and suicidal thoughts.

Yazdany says the program is compiling tools and resources to help clinicians refer patients to mental health resources, lupus support groups, and self-management programs. She is optimistic that the quality measures will also aid advocacy efforts to improve mental health services for people with lupus, although they don’t necessarily address common patient roadblocks like cost, transportation, and childcare.

The quality measures don’t include a recommendation for regular eye exams for patients taking hydroxychloroquine, which increases the risk of vision loss, because “ophthalmology visits are not reliably captured in the RISE registry,” Yazdany says.

The ACR’s Rheumatology Infomatics System for Effectiveness (RISE) registry is an EHR-based registry that includes patient data from more than 1,000 community rheumatologists across the country. The data can provide evidence of quality care and help drive quality improvement measures.

Yazdany says RISE has a large role in incorporating the new measures into clinical practice.

“We are in the process of doing detailed measure testing with rheumatology practices that participate in the RISE registry,” she says. “Once data capture and accuracy are verified, the measures will be incorporated into the RISE registry and automatically calculated for people with lupus nationwide. All participating rheumatology practices will be able to view their performance on the RISE registry dashboard.”

Yazdany continues, “It is evident that the commitment of rheumatologists addressing lupus-related health disparities is unwavering. We aimed for simplicity and high impact in these measures, envisioning their uniform implementation across the country. The strength lies in focusing on a few objectives for all to rally behind. Our hope is that implementation of these measures by 2030 will lead to reduced lupus- and steroid-related morbidity, improved functional outcomes, and reduced depression and suicide among people with lupus.”

This work was funded by the CDC through a collaborative agreement with the ACR.

###

About ACR Convergence

ACR Convergence, the annual meeting of the American College of Rheumatology, is where rheumatology meets to collaborate, celebrate, congregate, and learn. With more than 240 sessions and thousands of abstracts, it offers a superior combination of basic science, clinical science, business education and interactive discussions to improve patient care. For more information about the meeting, visit https://rheumatology.org/annual-meeting, or join the conversation on Twitter by following the official hashtag (#ACR23).

About the American College of Rheumatology

Founded in 1934, the American College of Rheumatology (ACR) is a not-for-profit, professional association committed to advancing the specialty of rheumatology that serves nearly 8,500 physicians, health professionals, and scientists worldwide. In doing so, the ACR offers education, research, advocacy and practice management support to help its members continue their innovative work and provide quality patient care. Rheumatology professionals are experts in the diagnosis, management and treatment of more than 100 different types of arthritis and rheumatic diseases. For more information, visit www.rheumatology.org.   

END



ELSE PRESS RELEASES FROM THIS DATE:

Study finds low anti-Ro titers are not associated with fetal heart block

2023-11-07
ATLANTA - New research from an ongoing study that will be presented at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, shows that pregnant women with very low titers of anti-Ro antibodies are at minimal to no risk of fetal atrioventricular (AV) block, a serious disorder affecting the heart’s electrical system. After birth, fetal AV block requires lifelong pacemaker treatment or cardiac transplantation and may be fatal. However, pregnant patients with higher titer antibodies seem to be at greatest risk  at risk ...

Study finds hydroxychloroquine lowers risk of nonalcoholic fatty liver disease in rheumatoid arthritis patients

2023-11-07
ATLANTA - New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, shows that treating rheumatoid arthritis with hydroxychloroquine (HCQ) reduced the risk of nonalcoholic fatty liver disease, especially in women and men who are 50 years old and younger (Abstract #0396). Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disease marked by chronic joint inflammation leading to joint damage and loss of function. It can also affect tissues and organs outside the joints, including (but not limited to) the eyes, ...

Study shows saliva gland abnormalities in Sjögren's worsens over time

2023-11-07
ATLANTA - New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, shows that ultrasound-detected salivary gland abnormalities in primary Sjögren's become more severe over time and that the slow-to-progress disease likely starts long before it is first detected (Abstract #1371).    Sjögren's disease also known as Primary Sjögren’s syndrome, is a systemic autoimmune disorder. It is marked by inflammation of the lacrimal and salivary glands, leading to chronic dry eyes and mouth. Fatigue is common, ...

Study finds positive antiphospholipid antibodies raises cardiovascular disease risk in patients with systemic lupus erythematosus

2023-11-07
ATLANTA — New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, describes a link between positive antiphospholipid antibodies and an increased risk of future cardiovascular disease in patients with systemic lupus erythematosus (SLE) (Abstract #0552). Antiphospholipid antibodies (aPLs) are autoantibodies directed against phospholipid-binding proteins. In antiphospholipid syndrome, they are associated with heart attack, stroke, and pulmonary embolism, and with miscarriage and stillbirth during pregnancy. People with SLE also have a greatly increased risk ...

Study finds JAK inhibitors and tocilizumab effective in VEXAS syndrome

2023-11-07
ATLANTA - New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, found that JAK inhibitors (JAKi) and tocilizumab elicited better response rates in VEXAS syndrome compared to other targeted therapies (Abstract #L03). VEXAS syndrome is a rare and often fatal autoimmune condition caused by a mutation in the UBA1 gene. It is marked by widespread inflammation leading to a range of symptoms that affect the skin, lungs, blood vessels and joints. The name is an acronym for disease characteristics: vacuoles in bone marrow, E1 enzyme (the enzyme encoded by the UBA1 gene), ...

Rheumatology training program for Native American primary care physicians expands reach

2023-11-07
ATLANTA — New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, describes the expansion of a novel program to train primary care physicians (PCPs) in the diagnosis and management of rheumatoid arthritis (RA) in Native American communities that have little or no access to rheumatology care (Abstract #2455). Despite the high prevalence of RA and other rheumatologic diseases among Native Americans, many Native American communities lack adequate access to subspecialized care. As a result, responsibility for treatment has shifted to primary care providers, who often do not feel confident prescribing RA medications or ...

Study finds TNF blockers are not associated with poor pregnancy outcomes

2023-11-07
ATLANTA — According to new research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, continuing tumor necrosis factor inhibitors during pregnancy is not associated with worse fetal or obstetric outcomes and may reduce the risk of severe maternal infections during pregnancy (Abstract #0477). Tumor necrosis factor (TNF) inhibitors such as adalimumab and infliximab are often prescribed for inflammatory forms of arthritis that have not improved with other treatments. Although studies suggest the drugs are safe during pregnancy, ...

Researchers identify incidence and risk factors for new-onset interstitial lung disease in systemic sclerosis

2023-11-07
ATLANTA - New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, reports the incidence and risk factors for new-onset interstitial lung disease (ILD) in previously ILD-negative systemic sclerosis patients (Abstract #1700). Interstitial lung disease is a common complication and cause of death in systemic sclerosis (SSc, scleroderma). Although the prevalence and risk factors for ILD are well known, less is known about the annual incidence and risk factors associated with the disease that occurs in patients who test negative on screening tests conducted at baseline. To answer these questions, Liubov Petelytska, ...

PET scans may predict Parkinson’s disease and Lewy body dementia in at-risk individuals

2023-11-07
In a small study, researchers at the National Institutes of Health have found that positron emission tomography (PET) scans of the heart may identify people who will go on to develop Parkinson’s disease or Lewy body dementia among those at-risk for these diseases. The findings, published in the Journal of Clinical Investigation and led by scientists at the National Institute of Neurological Disorders and Stroke (NINDS), part of NIH, may advance efforts to detect the earliest changes that years later lead to Parkinson’s disease and Lewy body dementia. In ...

Pioneering Sylvester physician elected to Society of Neuro-Oncology board

Pioneering Sylvester physician elected to Society of Neuro-Oncology board
2023-11-07
Macarena de la Fuente, MD, chief of neuro-oncology at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, has been elected to the Society of Neuro-Oncology (SNO)’s board of directors. She will serve as the neurology representative and becomes the first Hispanic elected to the multidisciplinary board, which strives to advance brain tumor research, education and collaboration. De la Fuente has been an SNO member for over a decade and previously served as chair of the society’s ...

LAST 30 PRESS RELEASES:

Personalized brain stimulation shows benefit for depression

AI uncovers hidden rules of some of nature’s toughest protein bonds

Innovative approach helps new mothers get hepatitis C treatment

Identifying the Interactions That Drive Cell Migration in Brain Cancer

ORNL receives 2025 SAMPE Organizational Excellence Award

University of Oklahoma researchers aim to reduce indigenous cancer disparities

Study reveals new evidence, cost savings for common treatments for opioid use disorder in mothers and infants

Research alert: Frequent cannabis users show no driving impairment after two-day break

Turbulence with a twist

Volcanic emissions of reactive sulfur gases may have shaped early mars climate, making it more hospitable to life

C-Path concludes 2025 Global Impact Conference with progress across rare diseases, neurology and pediatrics

Research exposes far-reaching toll of financial hardship on patients with cancer

The percentage of women who went without a Pap smear for cervical cancer screening increased following the COVID-19 pandemic, from 19% in 2019 to 26% in 2022

AI tools fall short in predicting suicide, study finds

Island ant communities show signs of ‘insect apocalypse’

Revealed: The long legacy of human-driven ant decline in Fiji

Analyzing impact of heat from western wildfires on air pollution in the eastern US

Inadequate regulatory protections for consumer genetic data privacy in US

Pinning down protons in water — a basic science success story

Scientists reveal how the brain uses objects to find direction

Humans sense a collaborating robot as part of their “extended” body

Nano-switch achieves first directed, gated flow of chargeless quantum information carriers

Scientist, advocate and entrepreneur Lucy Shapiro to receive Lasker-Koshland special achievement award

Creating user personas to represent the needs of dementia caregivers supporting medication management at home

UTIA participates in national study analyzing microbial communities, environmental factors impacting cotton development

Mizzou economists: 2025 farm income boosted by high cattle prices and one-time payments

What 3I/ATLAS tells us about other solar systems

University of Cincinnati allergist receives $300,000 grant to research rare esophageal disease

Ohio State scientists advance focus on nuclear propulsion

New study reveals a hidden risk after cervical cancer

[Press-News.org] Diverse task force develops new quality measures to improve lupus care by 2030